Rafferty Asset Management
SRNE

Rafferty Asset Management’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Rafferty Asset Management’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-4,394,415
Closed -$3.89M – 1180
2022
Q4 		$3.89M Buy
4,394,415
+1,399,741
+47% +$1.86M 0.03% 431
2022
Q3 		$4.7M Buy
2,994,674
+1,243,608
+71% +$2.82M 0.05% 345
2022
Q2 		$3.52M Sell
1,751,066
-719,616
-29% -$1.24M 0.03% 354
2022
Q1 		$5.76M Buy
2,470,682
+1,620,162
+190% +$5.05M 0.03% 349
2021
Q4 		$3.96M Buy
850,520
+457,080
+116% +$2.84M 0.02% 467
2021
Q3 		$3M Buy
393,440
+99,357
+34% +$842K 0.02% 478
2021
Q2 		$2.85M Sell
294,083
-30,980
-10% -$247K 0.02% 521
2021
Q1 		$2.69M Buy
325,063
+206,611
+174% +$2.18M 0.02% 548
2020
Q4 		$808K Sell
118,452
-195,498
-62% -$1.57M 0.01% 568
2020
Q3 		$3.5M Buy
313,950
+193,048
+160% +$1.77M 0.04% 242
2020
Q2 		$759K Buy
+120,902
New +$463K 0.01% 616

Other funds holding SRNE

PP
Paloma Partners Greenwich, Connecticut $1.36B AUM 249.29% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
OFA
Oaktree Fund Advisors Los Angles, California $57.8M AUM 67.22% 1-Year Est. Return
CGA
Crescent Grove Advisors Lake Forest, Illinois $1.2B AUM 23.08% 1-Year Est. Return
LCM
Lattice Capital Management Kirkland, Washington $49.5M AUM 28.58% 1-Year Est. Return
STB
S&T Bank Indiana, Pennsylvania $333M AUM 106.39% 1-Year Est. Return
GA
GoalVest Advisory New York $539M AUM 27.49% 1-Year Est. Return
HFRG
Houlihan Financial Resource Group Ashburn, Virginia $281M AUM 17.68% 1-Year Est. Return
VFA
Valeo Financial Advisors Carmel, Indiana $4.74B AUM 27.69% 1-Year Est. Return
GBWM
Granite Bay Wealth Management Portsmouth, New Hampshire $1.09B AUM 22.93% 1-Year Est. Return

Rafferty Asset Management's SRNE Position: Q1 2023 in Review

Rafferty Asset Management sold out of Sorrento Therapeutics, Inc. (SRNE) in Q1 2023, closing a stake of 4,394,415 shares — an estimated $3.89M sold.

Rafferty Asset Management first reported a position in SRNE in Q2 2020 and held it in 11 quarters. The position peaked at $5.76M in Q1 2022. 34 funds tracked by Wall St. Rank hold SRNE as of Q1 2023.

  • Rafferty Asset Management reported no remaining Sorrento Therapeutics, Inc. position as of Q1 2023 after selling out during the quarter.
  • Rafferty Asset Management sold 4,394,415 Sorrento Therapeutics, Inc. shares in Q1 2023, an estimated $3.89M.
  • Rafferty Asset Management first reported a position in Sorrento Therapeutics, Inc. in Q2 2020 and held it in 11 quarters.
  • Rafferty Asset Management's Sorrento Therapeutics, Inc. position peaked at $5.76M in Q1 2022.
  • 34 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q1 2023.

Based on Rafferty Asset Management's 13F filing for Q1 2023, filed 11 May 2023.